Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC

Trial Details

NCT ID
NCT04522544
Phase
PHASE2
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Tremelimumab
  • Durvalumab
  • Y-90 SIRT
  • DEB-TACE
Locations (sample)
  • Bonn, Germany|50.73438,7.09549
  • Cologne, Germany|50.93333,6.95
  • Essen, Germany|51.45657,7.01228
  • Freiburg im Breisgau, Germany|47.9959,7.85222
  • Göttingen, Germany|51.53443,9.93228

Key Eligibility Criteria

  • Capable of giving written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject p…
  • Age ≥ 18 years at time of study entry.
  • Body weight \> 30 kg.
  • Multinodular or large, solitary HCC, not eligible for resection or local ablation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →